What is the core difference between a conventional DMARD like methotrexate and an NSAID in treating rheumatoid arthritis?
Choose an answer, then check it.
Clinical Pharmacology · Anti-Inflammatory and Immunosuppressive Medications
Conventional DMARDs
On this page 6 sections
In 30 seconds
Conventional synthetic DMARDs (disease-modifying antirheumatic drugs) change the course of autoimmune joint disease rather than just masking its pain. Unlike NSAIDs or steroids, which quiet symptoms today, DMARDs suppress the immune process destroying cartilage and bone, and starting them early — within the "window of opportunity" — prevents damage that can never be undone later. Methotrexate is the anchor drug, and the single most important safety fact is that it is dosed weekly, never daily, because daily dosing has caused fatal toxicity. Hydroxychloroquine, sulfasalazine, leflunomide, and azathioprine round out the class, each with its own monitoring quirks.
The college version
Why "disease-modifying" matters
Rheumatoid arthritis and related autoimmune conditions involve chronic synovial inflammation that erodes cartilage and bone if unchecked. NSAIDs and corticosteroids reduce pain and swelling but do not stop that erosion. DMARDs interrupt the underlying immune signaling, slowing or halting structural damage. Because they take weeks to months to reach full effect, clinicians often bridge patients with short-term steroids or NSAIDs while the DMARD builds toward efficacy. The window-of-opportunity concept holds that the earlier a DMARD starts after diagnosis, the more damage is prevented; delaying treatment while chasing symptom relief alone lets irreversible damage accumulate. This pairs with treat-to-target: therapy is adjusted at set intervals based on measured disease activity until low activity or remission is reached, rather than continuing whatever was started first.
Methotrexate — the anchor drug
Methotrexate inhibits dihydrofolate reductase, an enzyme needed to regenerate active folate for DNA synthesis; at the low, intermittent doses used in rheumatic disease it also promotes adenosine release, adding its own anti-inflammatory effect. This mechanism and low exposure separate its rheumatologic use from the far higher, more frequent dosing used in oncology.
The defining safety principle is frequency: methotrexate for autoimmune disease is taken one day per week, not daily. Mistaking it for a daily medication is a documented cause of fatal toxicity, so education must confirm the weekly schedule before the first dose is dispensed. Folic acid is supplemented routinely to offset folate depletion and reduce mucosal and GI side effects without blunting disease-modifying action. Monitoring includes complete blood counts, liver enzymes, and renal function, since the drug can cause myelosuppression and hepatotoxicity and is renally cleared, so impaired kidney function raises levels. Other adverse effects include stomatitis, nausea and GI upset, and rarely pneumonitis. Methotrexate is contraindicated in pregnancy for both the partner who would carry a pregnancy and the partner contributing sperm, since it is teratogenic and affects sperm; reliable contraception is required for both. Key interactions: trimethoprim-sulfamethoxazole compounds folate antagonism and marrow suppression; NSAIDs and proton pump inhibitors can each reduce renal clearance of methotrexate and raise its levels.
Hydroxychloroquine
An antimalarial repurposed for lupus and mild rheumatoid arthritis, hydroxychloroquine has the most favorable safety profile of the class and is often used alone in mild disease or combined for more active disease. Its main long-term concern is retinopathy, so patients need baseline and periodic ophthalmologic screening to catch retinal changes before vision loss occurs.
Sulfasalazine
This molecule links a sulfa antibiotic component to an anti-inflammatory component, so sulfa-allergic patients need caution. It can interfere with folate absorption and commonly causes GI upset, so it is often started low and increased gradually.
Leflunomide
Leflunomide inhibits pyrimidine synthesis in activated lymphocytes and carries risks of hepatotoxicity and teratogenicity, requiring contraception. Its active metabolite undergoes enterohepatic recirculation and persists a very long time, so anyone needing rapid elimination — before pregnancy or after serious toxicity — requires a cholestyramine washout to bind the drug in the gut and speed clearance.
Azathioprine
Azathioprine is a purine analog that suppresses lymphocyte proliferation. Testing for TPMT and NUDT15 enzyme activity before starting identifies poor metabolizers at high risk for severe myelosuppression, allowing dose adjustment in advance. A dangerous interaction exists with allopurinol, which blocks the enzyme that breaks down azathioprine's active metabolite, risking profound marrow suppression unless doses are reduced.
Shared precautions
Because all conventional DMARDs suppress immune function, patients should be current on vaccinations before immunosuppression begins, since live vaccines may become unsafe afterward. Infection monitoring continues throughout treatment, with prompt reporting of fever or unusual fatigue.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your joints are being slowly chewed on by tiny invisible termites — that's the inflammation. Painkillers are like a nice-smelling candle in the room: it covers the smell, but the termites keep chewing. DMARDs are actual pest control — they go after the termites so the wood stops getting eaten, but pest control takes weeks to really work, so doctors sometimes light the candle for a while first. Methotrexate is the main spray, and here's the giant warning label: you spray it once a week, never every day, because spraying daily is way too much and can be deadly. The other medicines are backup pest-control tools, each with its own special instructions, like checking someone's eyes regularly or checking how their body handles the medicine before starting.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient calls saying they take their methotrexate "every morning" for arthritis. What should the nurse do and why?
Show answer
Stop the current dosing pattern immediately and contact the prescriber; daily methotrexate dosing is a known cause of fatal toxicity, so the schedule error must be corrected right away and the patient assessed for signs of toxicity.
This is a medication emergency because taking a weekly-only drug every day builds up to dangerous, potentially fatal levels rather than staying at a safe low weekly exposure.
Explain the "window of opportunity" concept and why it supports starting DMARD therapy early rather than waiting to see if symptoms worsen.
Show answer
The window of opportunity is the early period after diagnosis when starting a DMARD can still prevent much of the joint damage from ever happening, because eroded cartilage and bone do not reverse.
Waiting and treating only symptoms during this period lets the underlying inflammation keep destroying joint tissue, so starting DMARD therapy promptly protects joints that symptom-only treatment cannot.
Quick check
3 questions here. Answers stay hidden until you check.
Which statement about methotrexate dosing and safety is correct?
Choose an answer, then check it.
A patient starting leflunomide asks why she would ever need "cholestyramine" during treatment. What is the best explanation?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.